Skip to main content

Autoinflammatory

Canakinumab Use in Periodic Febrile Disorders

Sep 16, 2021

A retrospective records review of patients with periodic fever syndromes (PFS)  receiving IL-1 inhibitor treatment with canakinumab (CAN), shows CAN to be effective and safe in a variety of PFS patients.

Read Article

Pneumocystis Often Lethal in Dermatomyositis

MedPage Today
Sep 14, 2021

Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other antibody-negative idiopathic inflammatory myopathies, Chinese researchers found.

Read Article

ACR Guidance on Timing of 3rd Dose Booster with Immunomodulatory Drugs

ACR Press Release
Aug 25, 2021

The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases following recent recommendations from the CDC that certain immunocompromised patients receive a third dose of an available mRNA

Read Article
The CDC has reported that mRNA vaccine effectiveness against COVID-19–associated hospitalizations was sustained over 24 weeks; but there is evidence of waning protection amongst the immunosuppressed. https://t.co/UpQjFgKTpE https://t.co/3dQ2jacwJD
Dr. John Cush @RheumNow( View Tweet )
Aug 23, 2021

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Aug 13, 2021

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.




  1. In a head to head trial Upadacitinib was superior to Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. 24wk DBRCT, 924 pts given either UPA 30/d vsDUP 300 EOW. ESI75 response@

Read Article
New study data on mRNA vaccines in pts with inflammatory diseases on mostly #TNFi +/- #csDMARDs . ▶️ Effective immune response (lower than healthy controls) ▶️Comparable side effects ▶️ no ⬆️ in DAS28 ▶️ no pts on #Rituximab included https://t.co/aexdFoUzer https://t.co/h1S1S2YsHS
ARD & RMD Open @ARD_BMJ( View Tweet )
Aug 13, 2021

Anakinra's Effects on COVID-19 Outcomes

Aug 12, 2021

Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially highly elevated ferritin and C-reactive

Read Article

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

Aug 06, 2021

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.

Read Article
These companies do auto-inflammatory gene testing in the USA. @RWCSmtg https://t.co/89bWd0SiAI
Dr. John Cush @RheumNow( View Tweet )
Jul 08, 2021

ICYMI: 2020 Rheumatology Year in Review

Jul 08, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article
Video: What Kind of Diet Should You be on? with Dr. Robert Chao ( @doctorRBC) https://t.co/jqkA8vrgww #EULAR2021 https://t.co/5mPuZWmw20
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021
We need to revisit #SLEDAI #lupus arthritis. Drs Mahmoud & Vital reported only 48% without swelling had MSK-US synovitis; 90% with swelling. They proposed new TERM: Inflammatory joint pain with =>2 SJC. Need to get this right as it impacts SRI-4 #EULAR2021 #POS0746 @RheumNow https://t.co/JPqOMLQ2ES
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 05, 2021
Apremilast in Behcet’s - RELIEF European subgroup analysis ⬇️oral ulcer count, ulcer pain, disease activity ⬆️QoL ⭐️results consistent with general population Abs#POS0254 #EULAR2021 @RheumNow https://t.co/NVGt4TjkYY
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 05, 2021
Yesterday at #EULAR2021: Spacing trial: success in taper anti-TNF for stable SpA. POS0229 C-OPTIMSE study: Certolizumab w/d for SpA remission (continue full dose vs. 1/2 dose vs. placebo). Placebo group had ⬆️ activity scores, 77% flared. Ok to taper, but won't stop Rx @Rheumnow

Eric Dein @ejdein1( View Tweet )

Jun 05, 2021
#EULAR2021 - Key points from Dr. Mease's oral abstract: ⭐️AxSpA pts were younger & more likely to be male & have a hx of uveitis & IBD ⭐️AxSpA pts had less exposure to prior therapies relative to axPsA pts ⭐️AxSpA assoc w/ > spinal pain regardless of b/tsDMARD status @Rheumnow

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Jun 02, 2021
Dr Palomäki on influence of MUC5B promotor variant on ILD risk in RA and non-RA. Lifetime risk ILD 14.5% for RA+MUC5B+, 5.2% for RA+MUC5B-, 3.9% RA-MUC5B+ 1.3% RA-MUC5B- @RheumNow #EULAR2021 Abstr#OP0007 https://t.co/BnexQE1Pw9
Richard Conway @RichardPAConway( View Tweet )
Jun 02, 2021
Dr. G Robinson Abstr#OP0013 on sex link b/t autoimmune & CV risk 👉Hormones drive funx change in Treg transciptome 👉anti-inflamm Tregs⬆️in males 👉Tregs are more suppressive in males 👉Treg transciptome profile altered b/t males & females in autoimmunity #EULAR2021 @rheumnow https://t.co/p4Awfu2hiK
Jun 02, 2021
ILD in RA is a killer! @eular_org abst OP0099 Admin day from France claims database. ILD was clinically dx in 2.5% & had 3X mortality. Low prevalence compared to some studies of 6% so maybe worst cases but Impt cause of excess death in RA @RheumNow @eular_org @jeffsparks https://t.co/mPfpPSHxsd
Janet Pope @Janetbirdope( View Tweet )
Jun 02, 2021
Virtual DDW meeting this wk reports claims data comparing IBD to IBD with RA - IBD alone vs IBD w/ RA dx w/ more depression (21% vs 84%), anxiety (20% vs 47%). IBD w/ RA had more depression (OR 7.2); anxiety (OR, 1.25;) or both (OR, 2.3) https://t.co/B78xcJw584

Dr. John Cush @RheumNow( View Tweet )

May 27, 2021

Methotrexate Impairs COVID Vax Response

MedPage Today
May 27, 2021

One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.



In two independent cohorts, robust antibody responses were observed in 98.1% of healthy controls and in 91.9% of

Read Article
News: Factors Associated with COVID-19 Deaths in Rheumatic Patients https://t.co/FzsINtpZEz https://t.co/QzuLZRKaZy
Dr. John Cush @RheumNow( View Tweet )
May 25, 2021
Checkpoint Inhibitor Safety in Melanoma Patients with AID A study from the DMT shows that the use of checkpoint inhibitors for advanced melanoma in AID patients didn't increase the risk of irAEs, except for those with preexisting IBD. https://t.co/VFzBOlc0wc https://t.co/0zfr8YFmZr
Dr. John Cush @RheumNow( View Tweet )
May 20, 2021

Tocilizumab Risk of Diverticulitis and GI Perforation

May 19, 2021

A French registry analysis compared the risk of diverticulitis and gastrointestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with biologics and found a greater risk of both in patients receiving tocilizumab (TCZ) compared with those on rituximab (RTX) or abatacept (ABA

Read Article
Rituximab Tops Mycophenolate Mofetil for Pemphigus Vulgaris. One year study of 135 moderate-to-severe pemphigus patients saw complete remission in 40% of RTX vs 10% of MMF patients. https://t.co/yAauFRjHCe

Dr. John Cush @RheumNow( View Tweet )

May 19, 2021
"Arthritis Mutilans" - worse outcome to chronic inflammatory arthritis is due to 5 disorders: 1) RA 2) Psoriatic arthritis 3) Tophaceous gout 4) polyarticular JIA 5) Multicentric reticulohistiocytosis (Ive never seen this!!) https://t.co/XYmBEW1F0R https://t.co/tGWNG9Aklw

Dr. John Cush @RheumNow( View Tweet )

May 17, 2021
×